Tominaga Fukazawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tominaga Fukazawa has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Yohei Miyamoto
2 shared publicationsKanako Yajima
Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd
1 shared publicationYuri Yamazaki
1 shared publication
Latest Publications
- 1 May 2010
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 61 (3) , 329-333
Reduction of non-specific adsorption of drugs to plastic containers used in bioassays or analyses
- 1 May 2010
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 61 (3) , 329-333
Reduction of non-specific adsorption of drugs to plastic containers used in bioassays or analyses
- Open Access
- 1 January 2008
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 128 (10) , 1459-1465
Evaluation of Drug-drug Interaction Potential of Beraprost Sodium Mediated by P450 In Vitro
Beraprost sodium (BPS), a chemically stable and orally active prostacyclin analogue used for the treatment of chronic occlusive disease and primary pulmonary hypertension, was investigated in terms of its drug-drug interaction mediated by cytochrome P450. In a metabolic enzyme characterization study using P450-expressing insect cell microsomes, beraprost (BP) was slightly metabolized in the presence of CYP2C8, but not metabolized by the other P450 isoforms (CYP1A1, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP4A11) at a concentration of 20 μM. These results suggest that none of the P450 isoforms is a major metabolic enzyme of BP. In a P450 induction study using human hepatocytes, BP did not induce any P450 isoform (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) at concentrations of 1-100 μM. Furthermore, in a P450 inhibition study using human liver microsomes, BP did not inhibit any P450 isoform (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at concentrations of 0.05-1 μM. Therefore it is concluded that BP is not involved in drug-drug interaction mediated by P450 isoforms.
- 1 January 2008
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 128 (10) , 1459-1465
Open AccessEvaluation of Drug-drug Interaction Potential of Beraprost Sodium Mediated by P450 In Vitro
Beraprost sodium (BPS), a chemically stable and orally active prostacyclin analogue used for the treatment of chronic occlusive disease and primary pulmonary hypertension, was investigated in terms of its drug-drug interaction mediated by cytochrome P450. In a metabolic enzyme characterization study using P450-expressing insect cell microsomes, beraprost (BP) was slightly metabolized in the presence of CYP2C8, but not metabolized by the other P450 isoforms (CYP1A1, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP4A11) at a concentration of 20 μM. These results suggest that none of the P450 isoforms is a major metabolic enzyme of BP. In a P450 induction study using human hepatocytes, BP did not induce any P450 isoform (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) at concentrations of 1-100 μM. Furthermore, in a P450 inhibition study using human liver microsomes, BP did not inhibit any P450 isoform (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at concentrations of 0.05-1 μM. Therefore it is concluded that BP is not involved in drug-drug interaction mediated by P450 isoforms.